This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Evotec Reports Full-Year 2010 Results: A Good Year With A Strong Start Into 2011

Stocks in this article: EVT

HAMBURG, Germany, March 24, 2011 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today reported financial results and corporate updates for the year ended 31 December 2010.

  • STRONG 2010 RESULTS DRIVEN BY DRUG DISCOVERY ALLIANCES AND MILESTONES; ALL FINANCIAL TARGETS EXCEEDED
  • First time profitable in 18 year history: operating profit of € 1.7m (+104%), net result of € 3.0m (+107%)
  • Top-line revenue growth of +29% to € 55.3m, gross margin of 44.1%
  • Strong and stable liquidity position of € 70m despite acquisition
  • STRONG PORTFOLIO OF PERFORMANCE BASED DRUG DISCOVERY ALLIANCES: SOLID BASIS FOR GROWTH
  • Multiple new alliances and contract extensions
  • Significant licensing deal with MedImmune/AstraZeneca in metabolic diseases
  • GOOD PROGRESS IN DEVELOPMENT PARTNERSHIPS: SIGNIFICANT UPSIDE WITHOUT DEVELOPMENT RISK
  • Evotec's clinical programmes exclusively developed in partnerships; e.g. Phase II study ongoing with Roche in treatment resistant depression, Phase III ongoing with Teva in diabetes
  • SUCCESSFUL ACQUISITIONS OF DEVELOGEN AND KINAXO FOSTER INNOVATION POWER
  • Acquisition of Kinaxo opens path into oncology (after period end)
  • Acquisition of DeveloGen represents Best-in-class approach for beta cell regeneration and unique position in regenerative medicine
  • Harvard collaboration to expand leadership in beta cell technology (after period end)
  • GUIDANCE 2011 – ACCELERATED PATH TO GROWTH AND SUSTAINABILITY
  • Continued revenue growth of > 15% supported by strongest ever order book (€ 40m, +43% vs. 2010)
  • Improved operating result (before potential impairment)
  • Liquidity of more than € 65m despite significant investment programme and strong commitment to R&D platform technologies

1. Operational performance

Revenue growth of 29%, significantly improved operating result, first time profitable in Company history, strategic liquidity position stable at € 70m despite acquisition

With the Evotec 2012 Action Plan slightly ahead of plan, Evotec ended the year with a very good financial performance and also slightly exceeded the raised guidance from August 2010. The Company delivered on all financial targets. Evotec Group revenues amounted to € 55.3m, 29% above last year's level (2009: € 42.7m). This increase was due to a strong performance of the Company's discovery alliances, significant milestone achievements, stable license and upfront income, and additional revenues from the acquisition of DeveloGen (€ 0.8m). The achievement of four milestones from Boehringer Ingelheim in 2010, amounting to € 9.0m (2009: € 4.0m), highlights the continued solid progress that was made in several research programmes with this partner. Due to these milestone achievements the gross margin for the Group increased by 0.9%-points to 44.1% (2009: 43.2%).

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,345.50 -333.20 -1.88%
S&P 500 2,029.05 -28.04 -1.36%
NASDAQ 4,689.4710 -82.2920 -1.72%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs